Pioneering life-changing therapies through innovative sciencenoxopharm

LATEST NEWS
WHO WE ARE
Noxopharm Limited (ASX:NOX) is a clinical-stage Australian biotechnology company discovering and developing novel targeted therapies for chronic inflammation, autoimmune diseases and cancer, plus pioneering technology for mRNA vaccines and medicines.
 
 
Our innovative Sofra™ technology platform targets inflammation, autoimmunity, mRNA vaccine enhancement and cancer, providing the basis for active development of a growing pipeline of proprietary new drugs.

OUR TECHNOLOGY

 
Sofra
The Sofra™ technology platform comprises a pipeline of new proprietary drugs based on oligonucleotides, the building blocks of DNA or RNA, with a focus on mRNA vaccines and the treatment of autoimmune and inflammatory diseases.
 
Scientific Background
Read more about the groundbreaking immune system discovery underlying the Sofra platform – a discovery that pushes the frontiers of immunology and has far-reaching potential for the development of new medicines.
 
Veyonda®
Veyonda® is Noxopharm’s clinical drug candidate, currently in a phase 1 investigator-initiated clinical trial for the treatment of cancer in combination with immunotherapy.
 
My Title
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Duis rutrum sapien non ornare sagittis. Fusce quis dignissim felis. Pellentesque iaculis nisl et est ultricies, id mollis lorem volutpat. Praesent nec nunc vel quam facilisis scelerisque a ut orci. Sed sed enim vestibulum ex commodo venenatis vitae in mi. In eu velit sed nunc euismod tempor ac at odio. Mauris sit amet mi ac turpis rutrum congue sit amet id nunc.

"We are a highly dedicated group of experts who are dedicated to tackling some of the biggest challenges in medicine. We are leveraging specialist in-house capabilities and strategic partnerships with leading researchers to target autoimmune diseases and cancer, as well as developing technologies that will improve the effectiveness of mRNA vaccines. Our strategy is to deploy innovative approaches to developing new drugs, principally through research and development programs that explore the very building blocks of new treatments - the molecules and compounds that may one day save lives." 

Dr Olivier Laczka, CEO

Circle Box Image 1

Email icon